Completion of the Study of Yallaferon® in Cervicitis Patients

(Hong Kong, 20 December 2005) - Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: www.leespharm.com) today announced that the clinical study for cervicitis, a new indication for the Group's flagship product~Yallaferon® ("Recombinant Human Interferon α-2b gel") has been successfully completed.The goal of this clinical study was to demonstrate that Yallaferon® is safe and effective for the clinical treatment of patients with cervicitis.

The release as fetched from its publisher. leespharm.com ↗